Atossa Genetics (NASDAQ:ATOS) Coverage Initiated by Analysts at Rodman & Renshaw

Investment analysts at Rodman & Renshaw assumed coverage on shares of Atossa Genetics (NASDAQ:ATOS) in a report released on Tuesday. The firm set a “buy” rating and a $12.00 price target on the stock. Rodman & Renshaw’s price objective would suggest a potential upside of 426.32% from the stock’s current price.

Several other equities research analysts also recently commented on ATOS. Ascendiant Capital Markets dropped their price objective on shares of Atossa Genetics from $120.00 to $24.00 and set a “buy” rating on the stock in a report on Friday, April 10th. HC Wainwright increased their target price on Atossa Genetics to $25.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. Finally, Weiss Ratings cut Atossa Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th. Three research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $20.33.

Atossa Genetics Stock Performance

Atossa Genetics stock opened at $2.28 on Tuesday. Atossa Genetics has a fifty-two week low of $1.70 and a fifty-two week high of $19.35. The firm’s 50-day simple moving average is $4.00 and its 200 day simple moving average is $5.72. The stock has a market cap of $19.63 million, a PE ratio of -0.71 and a beta of 1.25.

Atossa Genetics (NASDAQ:ATOS) last announced its earnings results on Friday, May 8th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.12). As a group, analysts predict that Atossa Genetics will post -4.3 EPS for the current fiscal year.

Hedge Funds Weigh In On Atossa Genetics

A number of large investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in Atossa Genetics by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 6,078,844 shares of the company’s stock valued at $5,270,000 after buying an additional 245,717 shares during the last quarter. Ameriprise Financial Inc. bought a new stake in Atossa Genetics in the 2nd quarter worth $2,468,000. Renaissance Technologies LLC increased its position in shares of Atossa Genetics by 33.2% in the fourth quarter. Renaissance Technologies LLC now owns 2,062,838 shares of the company’s stock valued at $1,217,000 after acquiring an additional 514,175 shares during the period. Geode Capital Management LLC increased its position in shares of Atossa Genetics by 0.7% in the fourth quarter. Geode Capital Management LLC now owns 1,371,909 shares of the company’s stock valued at $810,000 after acquiring an additional 9,627 shares during the period. Finally, State Street Corp raised its stake in shares of Atossa Genetics by 31.2% during the fourth quarter. State Street Corp now owns 596,485 shares of the company’s stock valued at $352,000 after acquiring an additional 141,990 shares during the last quarter. 12.74% of the stock is owned by hedge funds and other institutional investors.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.